In vivo studies demonstrate enhanced inhibition of BRAFi-R melanoma growth following treatment with the combination of corin plus BRAFi versus corin alone, further supporting a role for CoREST inhibition in resensitizing BRAFi-R melanomas to BRAF therapies and suggesting a potential role for CoREST inhibition as a therapeutic modality to enhance MAPK-targeted therapies in patients with advanced melanoma. Here, CORIN is linked to melanoma.